AstraZeneca Pharma India credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
−449−449−537−506−500
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−0.51×−0.51×−0.70×−0.71×−0.85×
−1.95×−1.71×−2.11×−2.74×−3.03×
51.99×51.99×146.56×141.18×235.10×
As filed — company-reported covenants
————2.00×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ASTRAZEN₹6,299.00

AstraZeneca Pharma India Limited

· Pharma & Health
₹ CrorePeersSANOFICONRPGHLSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCMcap ₹15,748 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Net Debt-500.5-505.8-536.7-448.6-448.6
Net Debt/Equity-0.85-0.71-0.70-0.51-0.51
Net Debt/EBITDA-3.03-2.74-2.11-1.71-1.95
Interest Coverage (EBIT/Interest)235.10141.18146.5651.9951.99
As Filed — company-reported covenants
Debt/Equity (as filed)2.00————
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.